Antiviral therapy in chronic hepatitis C (G1) in Russia: cost and effectiveness
https://doi.org/10.22625/2072-6732-2015-7-1-91-98
Abstract
Genotype 1 HCV treatment in Russia assume as bitherapy (pegylated interferon – PG plus ribavirin – RBV) as three therapy based on HCV protease inhibitor such as telaprevir (TLV), boceprevir (BCV) or simeprevir (SMV) plus PG/RBV.
Medical technologies characterize neither clinical effectiveness, safety profile nor cost-effectiveness so it’s crucial to assess different costs related antiviral regimens.
Three therapy costs for naïve patients including TLV, BCV, SMV are higher bitherapy 2,6; 2,5; 3,1 times accordingly. Similar TLV and BCV effectiveness for naïve patients defines TLV or BCV as the preferable 1-st line regimen, depending on regional features of pricing.
SMV and TLV efficacy is similar among naïve patients and ralapsers but SMV is affordable for partially responders and non-responders after previous bitherapy. SMV cost is 1,4 times higher vs TLV but SMV has improved tolerability, less drug-drug interactions and shorter course.
Insufficient bitherapy effectiveness for G1 HCV (SVR 24 – 39%-55%) is required repeated course of three therapy for half of patient population. The first line regimen based on innovation will improve clinical outcomes for more patients and provide cost saving vs previous bitherapy based on PG/RBV.
About the Authors
A. V. Rudakova
Science Research Institute of Children’s Infections of FMBA of Russia, Saint-Petersburg, Russia
Russian Federation
Russian Federation
D. A. Gusev
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
A. N. Uskov
Science Research Institute of Children’s Infections of FMBA of Russia, Saint-Petersburg, Russia
Russian Federation
Russian Federation
Yu. V. Lobzin
Science Research Institute of Children’s Infections of FMBA of Russia, Saint-Petersburg, Russia
Russian Federation
Russian Federation
References
1. Пименов Н.Н., Чуланов В.П., Комарова С.В. и др. Гепатит С в России: эпидемиологическая характеристика и пути совершенствования диагностики и надзора // Эпидемиология и инфекционные болезни 2012; 3: 4-10.
2. Wendt A., Bourlière M. An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials // Ther. Adv. Infect. Dis. 2013; 1(6): 191-208.
3. Рекомендации по диагностике и лечению взрослых больных гепатитом С // Клинические перспективы гастроэнтерологии, гепатологии 2013; 2: 3-32.
4. Jacobson I., Dore G., Foster G., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial // Lancet 2014; 384: 403–13.
5. Wendt A., Bourlière M. An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials // Ther. Adv. Infect. Dis. 2013; 1(6): 191-208.
6. Kieran J., Schmitz S., O’Leary A., et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1 // Clinical Infectious Diseases 2013; 56(2): 228–35.
7. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection // N. Engl. J. Med. 2011; 364: 2405–16.
8. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV Infection // N. Engl. J. Med. 2011; 364: 2417-28.
9. Zeuzem S., Berg T., Gane, E., Ferenci, P., Foster, G., Fried, M. et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon ribavirin treatment: final SVR24 results of the ASPIRE trial // 2012; J. Hepatol. 56 (Suppl. 2): S1.
10. Manns M., Marcellin P., Poordad F., et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebocontrolled phase 3 trial // Lancet 2014; 384: 414–26.
11. Lawitz E., Forns X., Zeuzem S., et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from promise, a phase III trial [abstract no. 869b] // Digestive Disease Week; May 18– 21, 2013; Orlando, FL.
12. Zeuzem S., Berg T., Gane E., et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial // Gastroenterology epub Oct 31, 2013.
13. Kowdley K.V., Lawitz E., Crespo I., et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial // Lancet 2013; 381: 2100–2107.
14. Lawitz E., Lalezari J.P., Hassanein T., et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for noncirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial // Lancet Infect. Dis. 2013; 13: 401–408.
15. Lawitz E., Poordad F.F., Pang P.S., et al. Sofosbuvir and ledipasvir fixed dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial // Lancet 2013 Nov 1. doi: 10.1016/ S0140-6736(13)62121-2. [Epub ahead of print].
16. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al; AI444040 Study Group. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5a inhibitor) plus sofosbuvir (nucleotide NS5b inhibitor) with or without ribavirin, in treatment-naive patients chronically infected with HCV GT 1, 2, or 3. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA, 9–12 November 2012.
17. Jacobson I.M., Ghalib R.M., Rodriguez-Torres M., et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study [abstract LB-3]. 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1–5, 2013; Washington, DC.
18. Afdhal N.H., Zeuzem S., Schooley R.T., et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices // J. Viral Hepatol. 2013; 20:745–760.
19. Poordad F., Hezode C., Trinh R., et al. ABT-450/r–ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis [N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/ NEJMoa1402869. Epub 2014 Apr 11. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10.
20. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.
Review
For citations:
Rudakova A.V., Gusev D.A., Uskov A.N., Lobzin Yu.V. Antiviral therapy in chronic hepatitis C (G1) in Russia: cost and effectiveness. Journal Infectology. 2015;7(1):91-98. (In Russ.) https://doi.org/10.22625/2072-6732-2015-7-1-91-98
Views:
983
.png)
.png)
Email this article 